Smoking Cessation - Pipeline Review, H2 2015

Date: August 31, 2015
Pages: 110
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S9AA20E95DEEN
Leaflet:

Download PDF Leaflet

Smoking Cessation - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Smoking Cessation - Pipeline Review, H2 2015’, provides an overview of the Smoking Cessation’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Smoking Cessation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smoking Cessation and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Smoking Cessation
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Smoking Cessation and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Smoking Cessation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Smoking Cessation pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Smoking Cessation
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Smoking Cessation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Smoking Cessation Overview
Therapeutics Development
Pipeline Products for Smoking Cessation - Overview
Pipeline Products for Smoking Cessation - Comparative Analysis
Smoking Cessation - Therapeutics under Development by Companies
Smoking Cessation - Therapeutics under Investigation by Universities/Institutes
Smoking Cessation - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Smoking Cessation - Products under Development by Companies
Smoking Cessation - Products under Investigation by Universities/Institutes
Smoking Cessation - Companies Involved in Therapeutics Development
Aradigm Corporation
Arena Pharmaceuticals, Inc.
Astraea Therapeutics, LLC
Bioprojet SCR
Catalyst Biosciences, Inc.
CoMentis, Inc.
Embera NeuroTherapeutics, Inc.
FORUM Pharmaceuticals Inc.
GlaxoSmithKline Plc
Invion Limited
Johnson & Johnson
NAL Pharmaceuticals Ltd.
Pfizer Inc.
Pivot Pharmaceuticals Inc
Royalty Pharma
Selecta Biosciences, Inc.
Zynerba Pharmaceuticals, Inc.
Smoking Cessation - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(oxazepam + metyrapone) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anatabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARD-1600 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BP-1.4979 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs to Inhibit FAAH for CNS Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
encenicline hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-598809 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GTS-21 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNJ-39393406 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lorcaserin hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nadolol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NFL-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NIC7-DT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nicotine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nicotine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nicotine Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
P-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PF-05402536 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PF-06413367 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SEL-068 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Smoking Cessation and Appetite Suppression - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Agonize Alpha 4Beta 2 and Alpha 6Beta 2 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Agonize Neuronal Nicotinic Acetylcholine Receptor for Smoking Cessation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Agonize Alpha 4 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Nicotinic Acetylcholine Receptor for Smoking Cessation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Smoking Cessation - Recent Pipeline Updates
Smoking Cessation - Dormant Projects
Smoking Cessation - Discontinued Products
Smoking Cessation - Product Development Milestones
Featured News & Press Releases
Jun 29, 2015: Invion completes dosing in key phase II clinical trial of oral INV102 in smoking cessation
Feb 02, 2015: Invion completes enrolment in its phase II trial of oral INV102 (nadolol) in smoking cessation
Jan 19, 2015: Invion Announces Positive Interim Data from Its Phase II Clinical Trial of Oral Inv102 (nadolol) in Smoking Cessation
Nov 04, 2014: Lorcaserin Meets Primary Endpoint And Confirms Proof-Of-Concept As Potential Aid For Smoking Cessation In Investigational Phase II Clinical Study
Nov 03, 2014: Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 Trial of Lorcaserin HCl as an Aid for Smoking Cessation
Jul 01, 2014: Embera NeuroTherapeutics to Receive Grant for Clinical Trial Through New Crowd Funding Platform
May 09, 2014: Arena Pharmaceuticals Reports that Eisai Plans to Further Increase its Sales Force for BELVIQ (lorcaserin HCl) CIV by 50%
Jan 29, 2014: FDA clears path for “Smoking Cessation” clinical trial of INV102 (nadolol)
Nov 11, 2013: Change to FDA reviewing division for smoking cessation clinical trial
Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Smoking Cessation, H2 2015
Number of Products under Development for Smoking Cessation - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Smoking Cessation - Pipeline by Aradigm Corporation, H2 2015
Smoking Cessation - Pipeline by Arena Pharmaceuticals, Inc., H2 2015
Smoking Cessation - Pipeline by Astraea Therapeutics, LLC, H2 2015
Smoking Cessation - Pipeline by Bioprojet SCR, H2 2015
Smoking Cessation - Pipeline by Catalyst Biosciences, Inc., H2 2015
Smoking Cessation - Pipeline by CoMentis, Inc., H2 2015
Smoking Cessation - Pipeline by Embera NeuroTherapeutics, Inc., H2 2015
Smoking Cessation - Pipeline by FORUM Pharmaceuticals Inc., H2 2015
Smoking Cessation - Pipeline by GlaxoSmithKline Plc, H2 2015
Smoking Cessation - Pipeline by Invion Limited, H2 2015
Smoking Cessation - Pipeline by Johnson & Johnson, H2 2015
Smoking Cessation - Pipeline by NAL Pharmaceuticals Ltd., H2 2015
Smoking Cessation - Pipeline by Pfizer Inc., H2 2015
Smoking Cessation - Pipeline by Pivot Pharmaceuticals Inc, H2 2015
Smoking Cessation - Pipeline by Royalty Pharma, H2 2015
Smoking Cessation - Pipeline by Selecta Biosciences, Inc., H2 2015
Smoking Cessation - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Smoking Cessation Therapeutics - Recent Pipeline Updates, H2 2015
Smoking Cessation - Dormant Projects, H2 2015
Smoking Cessation - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Smoking Cessation, H2 2015
Number of Products under Development for Smoking Cessation - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED
Aradigm Corporation
Arena Pharmaceuticals, Inc.
Astraea Therapeutics, LLC
Bioprojet SCR
Catalyst Biosciences, Inc.
CoMentis, Inc.
Embera NeuroTherapeutics, Inc.
FORUM Pharmaceuticals Inc.
GlaxoSmithKline Plc
Invion Limited
Johnson & Johnson
NAL Pharmaceuticals Ltd.
Pfizer Inc.
Pivot Pharmaceuticals Inc
Royalty Pharma
Selecta Biosciences, Inc.
Zynerba Pharmaceuticals, Inc.
Skip to top


Smoking Cessation Therapy Area Pipeline Report US$ 1,495.00 Sep, 2010 · 134 pages
Smoking Cessation Aids Markets in China US$ 4,000.00 May, 2016 · 193 pages

Ask Your Question

Smoking Cessation - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: